| CEO Name | Sandy Macrae |
| Nationality | United Kingdom |
| Net Worth Estimation | $10 million |
Sandy Macrae, current CEO of Sangamo Therapeutics, has an estimated net worth of around $10 million primarily due to his executive compensation, stock holdings, and equity awards from Sangamo and previous leadership roles in the biotech sector. Public filings and SEC disclosures detailing his annual salary, bonuses, and vested stock options contribute to this valuation.
Sandy Macrae, CEO of Sangamo Therapeutics, has an estimated net worth of $10,000,000, which represents the minimum (12.5%) within the typical biotechnology CEO net worth range of $10,000,000 to $80,000,000. His net worth is at the lower end of the industry spectrum.
Business Category: Biotechnology
Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 80000000 USD
Sandy Macrae Performance in Sangamo Therapeutics
Sandy Macrae, CEO of Sangamo Therapeutics, demonstrates strategic leadership by driving innovation in gene editing and genomic medicine. His decision-making emphasizes advancing clinical programs and forging key partnerships, accelerating product development pipelines. Under his leadership, Sangamo has improved operational performance, enhanced shareholder value, and solidified its position as a leader in genome engineering.
Latest News
Sangamo Therapeutics CEO Sandy Macrae Leads Company Through Critical Pipeline and Financial Challenges
Sangamo Therapeutics, under CEO Sandy Macrae, is advancing its genomic medicine pipeline, including a Fabry disease gene therapy with positive registrational trial results and plans for a BLA submission in Q1 2026. Despite setbacks like Pfizer ending their hemophilia A gene therapy partnership and ongoing cash constraints, Sangamo continues to secure licensing deals and extend its operational runway.
Source: http://www.statnews.com/2024/12/30/hemophilia-pfizer-ends-gene-therapy-deal-with-sangamo/